What the FDA Relabeling of Abacavir Means for You and Your Patient
Introduction
November 2008
Welcome to Mayo Medical Laboratories’ Hot Topics. These presentations provide short discussions of current topics and may be helpful to you in your practice.
Our presenters for this program are Dr. Dennis O’Kane and Dr. Joseph Yao.
Dr. O’Kane is co-director of the nucleotide polymorphism laboratory in the division of clinical biochemistry and immunology. Dr. Yao is from the Division of Clinical Microbiology at Mayo Clinic.
Dr. O’Kane and Dr. Yao will be discussing the recent FDA safety alert linking potentially fatal hypersensitivity reactions with abacavir, a nucleoside RT inhibitor of Human Immunodeficiency Virus to a specific HLA-B allele, HLA-B*5701, and what this means for patient care.
Introduction |
Jump to section:
- Highly Active Antiretroviral Therapy
- Abacavir
- FDA Caution and Relabeling
- Abacavir Hypersensitivity
- Abacavir HSR and HLA Gene
- HLA-B Antigens and Alleles
- Naming Conventions - HLA-B*5701
- Chromosome 6
- Detecting HLA Alleles
- HLA-B*5701 Correlations
- HLA-B*5701 Correlations
- Clinical Utility3
- Problems
- If HSR Symptoms are Present4
- If HSR Symptoms are Present4
- Recommendations for Physicians5
- Recommendations for Physicians5
- Information for Patients5
- Information for Patients5
- HLA-B*5701 Genotyping
- References
- Questions?
External
link
PDF
document
Excel
document
Word
document